Design issues in randomized phase II/III trials

Journal of Clinical Oncology

Volumn 30, Issue 6, 2012, Pages 667-671

  Korn, Edward L ^a   Freidlin, Boris ^a   Abrams, Jeffrey S ^a   Halabi, Susan ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; SORAFENIB;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; LIVER CELL CARCINOMA; METASTASIS; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCREENING; SHORT SURVEY; TREATMENT OUTCOME; TREATMENT RESPONSE;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE; SINGLE-BLIND METHOD;

EID: 84857534782     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.5732     Document Type: Short Survey

References (23)

1. Thall PF, Simon R, Ellenberg SS: Two-stage selection and testing designs for comparative clinical trials. Biometrika 75:303-310, 1988
2. Schaid DJ, Wieand S, Therneau TM: Optimal two-stage screening designs for survival comparisons. Biometrika 77:507-513, 1990
3. Scher HI, Heller G: Picking the winners in a sea of plenty. Clin Cancer Res 8:400-404, 2002 (Pubitemid 34193956)
4. Bretz F, Schmidli H, König F, et al: Confirmatory seamless phase II/III clinical trials with hypothesis selection at interim: General concepts. Biom J 48:623-634, 2006 (Pubitemid 44367905)
5. Maca J, Bhattacharya S, Dragalin V, et al: Adaptive seamless phase II/III designs: Background, operational aspects, and examples. Drug Inf J 40:463-473, 2006 (Pubitemid 44721124)
6. Parmar MK, Barthel FM, Sydes M, et al: Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst 100:1204-1214, 2008
7. Hunsberger S, Zhao Y, Simon R: A comparison of phase II study strategies. Clin Cancer Res 15:5950-5955, 2009
8. Stallard N, Todd S: Seamless phase II/III designs. Stat Methods Med Res [epub ahead of print on August 19, 2010]
9. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
10. Korn EL, Arbuck SG, Pluda JM, et al: Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19:265-272, 2001 (Pubitemid 32063505)
11. Rubinstein LV, Korn EL, Freidlin B, et al: Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 23:7199-7206, 2005
12. Korn EL, Liu PY, Lee SJ, et al: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527-534, 2008 (Pubitemid 351264344)
13. Simon R, Wittes RE, Ellenberg SS: Randomized phase II clinical trials. Cancer Treat Rep 69: 1375-1381, 1985 (Pubitemid 16163075)
14. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
15. Bookman MA, Brady MF, McGuire WP, et al: Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the Gynecologic Cancer InterGroup. J Clin Oncol 27:1419-1425, 2009
16. Freidlin B, Korn EL, Gray R, et al: Multi-arm clinical trials of new agents: Some design considerations. Clin Cancer Res 14:4368-4371, 2008
17. Royston P, Barthel FM, Parmar MK, et al: Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit. Trials 12:81, 2011
18. Freidlin B, Korn EL: Monitoring for lack of benefit: A critical component of a randomized clinical trial. J Clin Oncol 27:629-633, 2009
19. Freidlin B, Korn EL, Gray R: A general inefficacy interim monitoring rule for randomized clinical trials. Clin Trials 7:197-208, 2010
20. Stadler WM, Phillips G, George DJ, et al: Bevacizumab and everolimus in renal cancer: A rational way forward. J Clin Oncol 33:e692-e693, 2010
21. Goldman B, Leblanc M, Crowley J: Interim futility analysis with intermediate endpoints. Clin Trials 5:14-22, 2008 (Pubitemid 351412367)
22. Green S: Pitfalls in oncology clinical trial designs and analysis, in Kelly WK, Halabi S (eds): Oncology Clinical Trials. New York, NY, Demos Medical Publishing, 2010, pp 197-214
23. Emerson SS, Fleming TR: Adaptive methods: Telling "the rest of the story." J Biopharm Stat 20:1150-1165, 2010